PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction
Summary
NIH's ClinicalTrials.gov registered a new Phase 3 clinical trial (NCT07533747) evaluating Empagliflozin 10mg for Coronary Microvascular Dysfunction (CMD). The trial aims to study heart energy metabolism in patients with CMD, a condition causing chest pain and shortness of breath without arterial blockages. No widely available proven treatments currently exist for CMD, making this a significant research effort targeting an unmet medical need.
What changed
NIH's ClinicalTrials.gov added a new Phase 3 clinical trial registration (NCT07533747) for PRECISE, studying Empagliflozin 10mg as an intervention for Coronary Microvascular Dysfunction (CMD). The trial will investigate heart energy metabolism and its relationship to symptoms in patients with CMD.
Affected parties include patients experiencing chest pain and shortness of breath without arterial blockages (small vessel angina), and the pharmaceutical sponsor conducting the trial. Healthcare providers treating CMD patients may follow trial progress as results could inform future treatment options for a condition currently lacking proven therapies.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction
Phase 3 NCT07533747 Kind: PHASE3 Apr 16, 2026
Abstract
Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram.
CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic.
This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.
Conditions: Coronary Microvascular Dysfunction (CMD)
Interventions: Empagliflozin 10mg OD
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.